More News

AstraZeneca $39 Billion Deal to Buy Alexion Expected to Close in Q3-2021
AstraZeneca $39 Billion Deal to Buy Alexion Expected to Close in Q3-2021

Alexion Pharmaceuticals, maker of Soliris (eculizumab) for the treatment of neuromyelitis optica spectrum disorder (NMOSD), is being acquired by the British-Swedish pharmaceutical company AstraZene...

2021 Glaucoma 360 Virtual Event Expands Audience to Nearly 100 Countries
2021 Glaucoma 360 Virtual Event Expands Audience to Nearly 100 Countries

Virtual meetings have allowed event coordinators to expand their reach into the homes, offices, and cell phones of participants all over the world. The 2021 Glaucoma 360 (G360) meeting extended par...

J&J Vision’s Eyhance is First Monofocal IOL Optimized  for Intermediate Vision in the US
J&J Vision’s Eyhance is First Monofocal IOL Optimized for Intermediate Vision in the US

Johnson & Johnson Vision announced Feb. 2 that it had gained US FDA approval of the TECNIS Eyhance lens, a new class of monofocal IOL we refer to as intermediate optimized. The approval included a ...

OIS Presbyopia Showcase Discusses Potential Impact of New Technology
OIS Presbyopia Showcase Discusses Potential Impact of New Technology

The Ophthalmology Innovation Summit (OIS) series of showcases in 2021 kicked off Jan. 28 with a discussion of unmet needs in the presbyopia market. Nine companies made presentations, and two separa...

Santen Launches Ducressa in Europe, Files NDA in the US for Eybelis
Santen Launches Ducressa in Europe, Files NDA in the US for Eybelis

Japanese drugmaker Santen announced Feb. 2 the European launch of Ducressa, a fixed-dose combination of an antibiotic (levofloxacin) and steroid (dexamethasone) designed as a seven-day treatment fo...

BVI Launches PhysIOL Podeye Toric IOL
BVI Launches PhysIOL Podeye Toric IOL

BVI announced Feb. 2 the European launch of the PhysIOL Podeye Toric intraocular lens, the first in a planned family of toric lenses built on its G-free (glistening-free) hydrophobic polymer materi...

New World Medical’s KDB Glide Goniotomy Knife Now Available for Purchase in US
New World Medical’s KDB Glide Goniotomy Knife Now Available for Purchase in US

New World Medical announced Feb. 17 that its KDB Glide knife for advanced excisional goniotomy in glaucoma patients is now commercially available in the US. The Rancho Cucamonga, California, compan...

US FDA PMA Approvals and 510(k) Clearances for January 2021
US FDA PMA Approvals and 510(k) Clearances for January 2021

The US FDA granted only one clearance through the 510(k) pathway for an ophthalmic device in January 2021, according to the FDA database. The device, from Luneau, is a follow-up device to the compa...

Market Scope Weekly Surgeon Poll for February 2021
Market Scope Weekly Surgeon Poll for February 2021

Tepezza Maker Horizon to Acquire Viela Bio for $3.05 Billion
Tepezza Maker Horizon to Acquire Viela Bio for $3.05 Billion

Horizon Therapeutics announced Feb. 1 that it had entered into a definitive agreement to acquire Viela Bio, in a deal worth approximately $3.05 billion. Horizon, headquartered in Dublin, Ireland, w...

EyePoint Leads Latest Fundraising Efforts with $100.1 Million Public Offering
EyePoint Leads Latest Fundraising Efforts with $100.1 Million Public Offering

EyePoint Pharmaceuticals, of Watertown, Massachusetts, led recent fundraising efforts by ophthalmic companies, with a $100.1 million underwritten public offering. Funding for the past four weeks to...

Glaucoma 360 Forum Looks at Four Potential Drug Innovations
Glaucoma 360 Forum Looks at Four Potential Drug Innovations

Four potential drug innovations under development were included in the Glaucoma 360 New Horizons Forum, held virtually on Jan. 30. Robert Dempsey, chief executive officer of TearClear, talked about...

Steady Growth,  New Technologies  Will Drive Retinal Surgery Device Market to $1.36 Billion in 2026
Steady Growth, New Technologies Will Drive Retinal Surgery Device Market to $1.36 Billion in 2026

The retinal surgical device market is expected to total more than $1.14 billion in 2021, with revenue rising to nearly $1.36 billion in 2026. Retinal surgical device sales are driven almost entirel...

New Era Arrives in Glaucoma Medication, With Transformative Tech
New Era Arrives in Glaucoma Medication, With Transformative Tech

The long-awaited start of the sustained drug-release era in glaucoma medication arrived in 2020 with Allergan’s launch of Durysta, a bimatoprost sustained release device. The launch came wrapped in...

Emerging Companies Pursuing Ophthalmic Indications, February 2021
Emerging Companies Pursuing Ophthalmic Indications, February 2021

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease. Company Location About CiRC Biosciences Chicago, Illinois Chicago-based Paragon Biosciences ...

February 2021 Ophthalmic News Briefs
February 2021 Ophthalmic News Briefs

The American Society of Cataract and Refractive Surgery has moved its 2021 annual meeting to Las Vegas from San Francisco and changed the dates to July 23-27 from Aug. 13-17. The meeting originally...

​​​​​​​Ophthalmic Fundraising Activity Soars in Face of Pandemic
​​​​​​​Ophthalmic Fundraising Activity Soars in Face of Pandemic

The ophthalmic market continues to expand and attract funding from investors. There were more deals in 2020 than the two previous years, and transactions totaled $8.6 billion. Retina is the largest...

Faricimab Extends Treatment Time to Four Months in Nearly Half of Phase III Subjects
Faricimab Extends Treatment Time to Four Months in Nearly Half of Phase III Subjects

Genentech, a member of the Roche Group, reported Feb. 12 that its retinal drug candidate faricimab extended the time between treatments up to four months for nearly half the subjects in Phase III t...

New World Medical’s KDB Glide Goniotomy Knife Now Available for Purchase in US
New World Medical’s KDB Glide Goniotomy Knife Now Available for Purchase in US

New World Medical announced Feb. 17 that its KDB Glide knife for advanced excisional goniotomy in glaucoma patients is now commercially available in the US. The Rancho Cucamonga, California, compan...

Heine Launches Omega 600 Lightweight Indirect Ophthalmoscope
Heine Launches Omega 600 Lightweight Indirect Ophthalmoscope

Heine has launched its Omega 600 indirect ophthalmoscope in the US and Canada. It will be available globally in May, the company said. The German company said the Omega 600 is the lightest high-end...

Akorn Receives FDA Approval for Generic Loteprednol Etabonate Ophthalmic Gel, 0.5%
Akorn Receives FDA Approval for Generic Loteprednol Etabonate Ophthalmic Gel, 0.5%

Akorn, of Lake Forest, Illinois, announced Feb. 11 that it had received approval of its abbreviated new drug application (ANDA) from the US FDA for loteprednol etabonate ophthalmic gel, 0.5%. The f...

Glaucoma Drug Vyzulta Gains Approval in South Korea
Glaucoma Drug Vyzulta Gains Approval in South Korea

Canada-based Bausch Health and French company Nicox announced Feb. 9 that Vyzulta (latanoprostene bunod ophthalmic solution), 0.024%, had received regulatory approval from the Ministry of Food and ...

Lumibird Opens Three Scandinavian Sales Subsidiaries
Lumibird Opens Three Scandinavian Sales Subsidiaries

The medical division of French laser company Lumibird announced Feb. 9 that it had created three subsidiaries in Sweden, Finland, and Norway. With these three new subsidiaries, Lumibird Medical Nor...

LumiThera Shares Positive Results of Photobiomodulation in Dry AMD
LumiThera Shares Positive Results of Photobiomodulation in Dry AMD

LumiThera, maker of the Valeda photobiomodulation system for dry age-related macular degeneration (AMD), on Feb. 16 shared positive interim data from its ELECTROLIGHT pilot study. LumiThera obtaine...

Melt Completes Phase I Study for Sublingual Pain and Sedation Drug Candidate
Melt Completes Phase I Study for Sublingual Pain and Sedation Drug Candidate

Melt Pharmaceuticals announced Feb. 9 that it had completed a Phase I study of its Melt sublingual, non-opioid pain and sedation drug candidate for patients undergoing cataract surgery. Two dosage ...

Trefoil Begins Phase II Trial of Regenerative Treatment for Fuchs’ Dystrophy
Trefoil Begins Phase II Trial of Regenerative Treatment for Fuchs’ Dystrophy

Trefoil Therapeutics announced Feb. 9 that it has begun a Phase II clinical trial of its engineered fibroblast growth factor-1, TTHX1114, as a regenerative treatment for patients with Fuchs’ endoth...

AcuSurgical Raises $6.95 Million in Series A to Advance Robotic Ocular Microsurgery Platform
AcuSurgical Raises $6.95 Million in Series A to Advance Robotic Ocular Microsurgery Platform

AcuSurgical announced Feb. 18 that it had raised €5.75 million (US $6.95 million) in a Series A financing round. The company, founded in 2020 and based in Montpellier, France, is advancing a roboti...

Bionic Vision Awarded $775 Thousand Medical Research Future Fund Grant
Bionic Vision Awarded $775 Thousand Medical Research Future Fund Grant

Bionic Vision Technologies announced Feb. 16 that it had received a grant in late 2020 of AUD $1 million (US $775 thousand) to advance its retinal prosthesis technology and vision processing algori...

Santen Launches Ducressa in Europe, Files NDA for Eybelis in US
Santen Launches Ducressa in Europe, Files NDA for Eybelis in US

Japanese drugmaker Santen announced Feb. 2 the European launch of Ducressa, a fixed-dose combination of an antibiotic (levofloxacin) and steroid (dexamethasone) designed as a seven-day treatment fo...

BVI Launches PhysIOL Podeye Toric IOL
BVI Launches PhysIOL Podeye Toric IOL

BVI announced Feb. 2 the European launch of the PhysIOL Podeye Toric intraocular lens, the first in a planned family of toric lenses built on its G-free (glistening-free) hydrophobic polymer materi...

Turn Biotechnologies Acquires Second Stem Cell Technology from Stanford
Turn Biotechnologies Acquires Second Stem Cell Technology from Stanford

Turn Biotechnologies, of Mountain View, California, reported Feb. 3 that it had acquired the global rights from Stanford University for “artificial niche” technology that can be used to restore mus...

EssilorLuxottica, Cooper Team Up to Acquire SightGlass Vision
EssilorLuxottica, Cooper Team Up to Acquire SightGlass Vision

EssilorLuxottica and CooperCompanies announced Feb. 3 that they would create a 50/50 joint venture for the acquisition of SightGlass Vision, developer of spectacle lenses to slow the progression of...

Exonate Starts Phase Ib/II Trial of Eye Drop for DME
Exonate Starts Phase Ib/II Trial of Eye Drop for DME

British company Exonate announced Feb. 2 that the first patient had been dosed in a Phase Ib/II trial of its lead compound EXN 407, an eye drop targeting center-involved diabetic macular edema (DME...

GenSight Recruits Patients with RP for Study of Potential Optogenetic Therapy
GenSight Recruits Patients with RP for Study of Potential Optogenetic Therapy

French company GenSight Biologics reported Feb. 4 that it is recruiting patients with retinitis pigmentosa and bare light perception for a Phase I/II clinical trial to investigate its optogenetic t...

Neurophth Raises $61.9 Million in Series B Financing
Neurophth Raises $61.9 Million in Series B Financing

Neurophth Therapeutics announced Feb. 9 that it had raised $61.9 million in a Series B round led by Guofang Capital and InnoVision Capital. The Wuhan, China-based company aims to be the first Chine...

Ocugen Raises $23 Million in Registered Direct Offering of Common Stock
Ocugen Raises $23 Million in Registered Direct Offering of Common Stock

Ocugen, of Malvern, Pennsylvania, announced Feb. 10 that it had closed a registered direct offering of 3 million shares, for gross proceeds of approximately $23 million. H.C. Wainwright & Co. acted...

Biophytis Raises $20.1 Million in IPO
Biophytis Raises $20.1 Million in IPO

Drug developer Biophytis raised $20.1 million in gross proceeds on Feb. 10 in an initial public offering of 1.2 million American Depositary Shares, representing 12 million new ordinary shares, at $...

Tepezza Maker Horizon to Acquire Viela Bio for $3.05 Billion
Tepezza Maker Horizon to Acquire Viela Bio for $3.05 Billion

Horizon Therapeutics announced Feb. 1 that it had entered into a definitive agreement to acquire Viela Bio, in a deal worth approximately $3.05 billion. Horizon, headquartered in Dublin, Ireland, w...

Latest Ophthalmic Meeting News: ASCRS Changes, Winning Pitch Challenge, Next OIS Showcase
Latest Ophthalmic Meeting News: ASCRS Changes, Winning Pitch Challenge, Next OIS Showcase

The American Society of Cataract and Refractive Surgery has moved its 2021 annual meeting to Las Vegas from San Francisco and changed the dates to July 23-27 from Aug. 13-17. The Mandalay Bay Conve...

Immunovant Pauses Trial for TED Candidate due to Elevated Cholesterol
Immunovant Pauses Trial for TED Candidate due to Elevated Cholesterol

Immunovant has paused dosing in its ongoing clinical trials for IMVT-1401 subcutaneous injection in autoimmune diseases, including thyroid eye disease (TED), the company announced Feb. 2. Elevated ...

2020 Earnings Roundup: Regeneron, Nicox, Hoya, and Four More
2020 Earnings Roundup: Regeneron, Nicox, Hoya, and Four More

Regeneron, of Tarrytown, New York, reported Q4-2020 revenue of $2.42 billion, a 30.1 percent increase over Q4-2019 revenue of $1.86 billion. Full year 2020 revenue was $8.50 billion, a 30 percent i...

Bariatric Surgery May Curb Diabetic Retinopathy Incidence but Worsen Existing Cases
Bariatric Surgery May Curb Diabetic Retinopathy Incidence but Worsen Existing Cases

Bariatric surgery was associated with fewer cases of diabetic retinopathy (DR), but early worsening was more severe in patients who already had the condition, according to a Reuters Health report a...

Mati Secures IP for Evolute Punctal Plug Delivery System from Novelion, formerly QLT
Mati Secures IP for Evolute Punctal Plug Delivery System from Novelion, formerly QLT

Mati Therapeutics, of Austin, Texas, announced Feb. 1 that it had purchased all rights related to its Evolute Punctal Plug Delivery System (PPDS) from Novelion Therapeutics (formerly QLT), which is...

Paragon Launches CiRC Cell Therapy Company Targeting GA
Paragon Launches CiRC Cell Therapy Company Targeting GA

Chicago-based Paragon Biosciences announced Feb. 2 that it has launched CiRC Biosciences, a cell therapy company with an initial focus on the eye. CiRC is advancing a preclinical-stage technology i...

Surface Doses First Patient in Head-to-Head Phase II Trial for SURF-100 for Chronic Dry Eye
Surface Doses First Patient in Head-to-Head Phase II Trial for SURF-100 for Chronic Dry Eye

Surface Ophthalmics announced Jan. 27 that the first patient had been dosed in its Phase II clinical trial for SURF-100 (mycophenolate sodium and betamethasone sodium phosphate in Klarity vehicle) ...

Outlook Raises $41.6 Million to Support Lytenava through BLA Submission
Outlook Raises $41.6 Million to Support Lytenava through BLA Submission

Outlook Therapeutics announced Feb. 4 that it had raised a total of $41.6 million to support the development of Lytenava, which, if approved, would be the first US FDA-approved ophthalmic formulati...

EyePoint Raises $100.1 Million in Public Offering of Common Stock
EyePoint Raises $100.1 Million in Public Offering of Common Stock

EyePoint Pharmaceuticals, maker of Yutiq and Dexycu, announced Feb. 1 that it had priced an underwritten public offering of 9.1 million shares of its common stock at $11 per share. Gross proceeds w...

AGTC Prices $74.5 Million Public Offering of Common Stock and Warrants
AGTC Prices $74.5 Million Public Offering of Common Stock and Warrants

Applied Genetic Technologies Corporation (AGTC) announced Jan. 28 that it had priced a public offering of 16.7 million shares of common stock, with accompanying warrants to purchase 8.4 million sha...

Ocutrx Names William Link Chairman of Scientific Advisory Board
Ocutrx Names William Link Chairman of Scientific Advisory Board

Ocutrx Technologies, of Irvine, California, announced Jan. 27 that it had appointed William Link, PhD, as chairman of its International Scientific Advisory Board. Ocutrx’ pipeline of devices includ...

SparingVision Appoints Daniel Chung as Chief Medical Officer
SparingVision Appoints Daniel Chung as Chief Medical Officer

Paris-based SparingVision announced Feb. 4 that it had appointed Daniel Chung, DO, as chief medical officer. Chung led the global medical strategy for ophthalmology at Spark Therapeutics, which dev...

Want to Read Locked Articles?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more

Market Scope

13421 Manchester Road, Suite 101 | St. Louis, MO 63131 | Phone: 314-835-0600 | Email: info@market-scope.com

©2021 Market Scope, LLC. All Rights reserved.